RT Journal Article SR Electronic T1 Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study JF Journal of Clinical Pathology JO J Clin Pathol FD BMJ Publishing Group Ltd and Association of Clinical Pathologists SP 58 OP 60 DO 10.1136/jclinpath-2020-207107 VO 75 IS 1 A1 Iaccarino, Antonino A1 Pisapia, Pasquale A1 Pepe, Francesco A1 Sgariglia, Roberta A1 Nacchio, Mariantonia A1 Russo, Gianluca A1 Gragnano, Gianluca A1 De Luca, Caterina A1 Troncone, Giancarlo A1 Malapelle, Umberto YR 2022 UL http://jcp.bmj.com/content/75/1/58.abstract AB V-Raf murine sarcoma viral oncogene homolog B (BRAF) gene mutations have recently been approved to select advanced stages non-small cell lung cancer (NSCLC) patients for tyrosine kinase inhibitors treatments. In this setting, liquid biopsy may represent a valuable option for BRAF mutational testing in patients without tissue availability. Here, we reviewed 196 plasma based liquid biopsies analysed by an in-house developed next generation sequencing panel, termed SiRe. On the overall, 6 (3.1%) out of 196 BRAF mutated cases were identified, with an overall median allelic frequency of 3.4%. Exon 15 p.V600E was the most common detected mutation (2/6, 33.3%). Our data highlighted that the SiRe panel is a robust tool for BRAF mutation assessment on circulating tumour DNA. Further investigation is required to develop a diagnostic algorithm to harmonise BRAF testing on tissue and blood in advanced stages NSCLC patients.